Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination.
Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination.
复制标题
DOI：
10.1136/bcr-2021-242220
复制
发表时间：
2021-05-31
期刊：
影响因子：
0.9
通讯作者：
García-Salcido MÁ
中科院分区：
文献类型：
--
作者：
Fueyo-Rodriguez O;Valente-Acosta B;Jimenez-Soto R;Neme-Yunes Y;Inclán-Alarcón SI;Trejo-Gonzalez R;García-Salcido MÁ
免疫性血小板减少症（ITP）已被广泛报道为SARS-CoV-2感染的并发症，但据我们所知，尚未有COVID-19疫苗与血小板减少症相关的报道。在这里，我们报告了一例继发性ITP患者，该患者最近接种了信使RNA COVID-19疫苗BNT 162 b2（Pfizer-BioNTech）。
Immune thrombocytopenia (ITP) has been widely reported as a complication of SARS-CoV-2 infection, but to our knowledge, there have been no reports on the association of the COVID-19 vaccine with thrombocytopenia. Here, we report a case of secondary ITP in a patient who was recently immunised with the messenger RNA COVID-19 vaccine BNT162b2 (Pfizer–BioNTech).